Kilitch Drugs (India) Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3bmq2iw1q4fq0avnhh88352t.pdf

Key Takeaways


Ethiopia: The Restart and the Forex Gate

Mukund Mehta: "First, there was internal fighting going on for 1.5 year, which has settled just two months before. ... But everything settled down. And from 1.5 month, everything is working now."

Ethiopia: The Margin and Market Structure

Mukund Mehta: "There is no question of margin as we are the only manufacturer and government is supporting in all the ways. So I don't see, I don't say, no question of margin arises. You have goods, you sell at any cost, no one is saying."

Injectable Capacity and the Khopoli Project

Bhavin Mehta: "...looking forward, we feel that next one year, 1.5 year or maximum two years, we'll be in, requiring additional capacity. So because of which, the Khopoli project has been conceptualized..."

Domestic and Export Business


UN Agency and Africa Strategy

Bhavin Mehta: "This concept of their buying from outside Africa, we wish to change. Since, we are one of the biggest capacities in terms of setup in Ethiopia and we are in Africa. So the concept is well bought by all the UN agencies and we are following the pathway by which, we produce in Africa and where we sell in Africa."

Guidance & Commitments

CommitmentSpecificsTimeline
Ethiopia forex resolutionGovernment announcement on economic opening expectedJuly–August 2023
Ethiopia government tender supplyGo-ahead on US-dollar payment proposal expected"Very few months this year"
Ethiopia export registrationsProducts registered in seven to eight targeted countries"In a year or two years"
Khopoli plant production startFactory to begin producingMarch 2025 onwards
UN agency procurement accessWHO Geneva and EU approvals for Ethiopia factory"In a year or two"
Domestic growthDouble-digit YoY growthContingent on government healthcare spend

Key Metrics

MetricQ4 FY23
Standalone operating revenue₹43.28 cr, growth of 35.12% YoY
Standalone EBITDA₹8.12 cr, growth of 71.31% YoY
Standalone EBITDA margin18.76%, improved from 14.11% YoY
Standalone PAT₹5.13 cr, growth of 69.87% YoY
Standalone EPS₹3.29 per share, up from ₹1.94 per share YoY
FY23 standalone operating revenue₹117.78 cr, increase of 12% YoY
FY23 standalone EBITDA₹21.74 cr, growth of 39.91% YoY
FY23 standalone EBITDA margin18.8%, improved from 14.80% YoY
FY23 standalone PAT₹15.72 cr, growth of 49.29% YoY
FY23 standalone EPS₹10.09 per share, up from ₹6.76 per share YoY
Export commission and registration expense (Q4)₹5.4 cr
Export commission and registration expense (FY23)₹11.42 cr, more than double the previous year's ~₹5.48 cr
Export commission rate8% to 15% of sales, depending on the market
Ethiopian Cephalosporin plant capacity~1.6–1.7 cr vials per year
Ethiopian government Cephalosporin requirement2.5 cr vials per year
Products registered across the worldOver 600
Products under registration process450 plus
African portfolio350 products across 26 countries
Khopoli Greenfield project capexMore than ₹100 cr
Khopoli plant expected production startMarch '25 onwards
Ethiopia JV structure67% Kilitch, 33% local distributor
Ethiopia tax holiday4 years income tax benefit, started 21 July '21, due till July '25
Cephalosporin private market realization (Ethiopia)30–35 birr
Khopoli plant fundingSanctions from banks obtained, external loan